Kathryn L Chapman

Summary

Country: UK

Publications

  1. doi request reprint A global pharmaceutical company initiative: An evidence-based approach to define the upper limit of body weight loss in short term toxicity studies
    Kathryn Chapman
    UK National Centre for the Replacement, Refinement and Reduction of Animals in Research NC3Rs, Gibbs Building, 215 Euston Road, London NW1 2BE, UK Electronic address
    Regul Toxicol Pharmacol 67:27-38. 2013
  2. doi request reprint Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translation
    Kathryn L Chapman
    UK National Centre for the Replacement, Refinement and Reduction of Animals in Research NC3Rs, Gibbs Building, 215 Euston Road, London, NW1 2BE, UK Electronic address
    Regul Toxicol Pharmacol 66:88-103. 2013
  3. doi request reprint The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates
    Kathryn L Chapman
    National Centre for Replacement, Refinement and Reduction of Animals in Research, Gibbs Building, 215 Euston Rd, London NW1 2BE, UK
    Regul Toxicol Pharmacol 62:347-54. 2012
  4. ncbi request reprint Preclinical safety testing of monoclonal antibodies: the significance of species relevance
    Kathryn Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B 1AL, UK
    Nat Rev Drug Discov 6:120-6. 2007
  5. pmc Preclinical development of monoclonal antibodies: considerations for the use of non-human primates
    Kathryn Chapman
    National Centre for Replacement, Refinement and Reduction of Animals in Research, London, UK
    MAbs 1:505-16. 2009
  6. doi request reprint The future of non-human primate use in mAb development
    Kathryn L Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK
    Drug Discov Today 15:235-42. 2010
  7. doi request reprint The value of acute toxicity studies to support the clinical management of overdose and poisoning: a cross-discipline consensus
    Kathryn Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, UK
    Regul Toxicol Pharmacol 58:354-9. 2010
  8. doi request reprint Working in partnership to advance the 3Rs in toxicity testing
    Anthony M Holmes
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK
    Toxicology 267:14-9. 2010
  9. doi request reprint A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development
    Sally Robinson
    AstraZeneca, Alderley Park, UK
    Regul Toxicol Pharmacol 50:345-52. 2008

Collaborators

Detail Information

Publications9

  1. doi request reprint A global pharmaceutical company initiative: An evidence-based approach to define the upper limit of body weight loss in short term toxicity studies
    Kathryn Chapman
    UK National Centre for the Replacement, Refinement and Reduction of Animals in Research NC3Rs, Gibbs Building, 215 Euston Road, London NW1 2BE, UK Electronic address
    Regul Toxicol Pharmacol 67:27-38. 2013
    ..The data analysis supports BWL limits for short term dosing (up to 7days) of 10% for rat and dog and 6% for non-human primates (NHPs). ..
  2. doi request reprint Pharmaceutical toxicology: Designing studies to reduce animal use, while maximizing human translation
    Kathryn L Chapman
    UK National Centre for the Replacement, Refinement and Reduction of Animals in Research NC3Rs, Gibbs Building, 215 Euston Road, London, NW1 2BE, UK Electronic address
    Regul Toxicol Pharmacol 66:88-103. 2013
    ..Through providing a forum for open discussion of novel proposals, reviewing current research and obtaining expert opinion in each of the four areas, the authors have developed recommendations on good practice and future strategy...
  3. doi request reprint The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates
    Kathryn L Chapman
    National Centre for Replacement, Refinement and Reduction of Animals in Research, Gibbs Building, 215 Euston Rd, London NW1 2BE, UK
    Regul Toxicol Pharmacol 62:347-54. 2012
    ..They include guidance on the main group size, the inclusion of recovery groups and the number of dose groups used in short and long term chronic toxicology studies...
  4. ncbi request reprint Preclinical safety testing of monoclonal antibodies: the significance of species relevance
    Kathryn Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B 1AL, UK
    Nat Rev Drug Discov 6:120-6. 2007
    ....
  5. pmc Preclinical development of monoclonal antibodies: considerations for the use of non-human primates
    Kathryn Chapman
    National Centre for Replacement, Refinement and Reduction of Animals in Research, London, UK
    MAbs 1:505-16. 2009
    ..The addendum of ICHS6 provides a timely opportunity for the scientific and regulatory community to embrace strategies which minimize primate use and increase efficiency of mAb development...
  6. doi request reprint The future of non-human primate use in mAb development
    Kathryn L Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK
    Drug Discov Today 15:235-42. 2010
    ..In this article, the authors review current and future NHP use in mAb development based on surveys, experience and expert opinion and propose a framework that will minimize future NHP use and continue to support science and innovation...
  7. doi request reprint The value of acute toxicity studies to support the clinical management of overdose and poisoning: a cross-discipline consensus
    Kathryn Chapman
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, UK
    Regul Toxicol Pharmacol 58:354-9. 2010
    ....
  8. doi request reprint Working in partnership to advance the 3Rs in toxicity testing
    Anthony M Holmes
    National Centre for the Replacement, Refinement and Reduction of Animals in Research, 20 Park Crescent, London W1B1AL, UK
    Toxicology 267:14-9. 2010
    ..This review highlights the mechanisms by which the NC3Rs is working with the pharmaceutical and chemical industries and regulatory authorities to achieve these goals...
  9. doi request reprint A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development
    Sally Robinson
    AstraZeneca, Alderley Park, UK
    Regul Toxicol Pharmacol 50:345-52. 2008
    ..The conclusions have been discussed and agreed with representatives of regulatory bodies from the US, Japan and Europe...